Chronic Lyme disease and co-infections: Differential diagnosis

Open Neurology Journal

Volumn 6, Issue SPEC.ISS.1, 2012, Pages 158-178

  Berghoff, Walter ^a  

^a Practice of Internal Medicine   (Germany)

Author keywords

Bartonellosis; Borellia burgdorferi; Chlamydia trachomatis; Chlamydophila pneumoniae; Co infection; Lyme disease; Mycoplasma pneumoniae; Treatment; Yersinia enterocolitica

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CARBAPENEM; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GEMIFLOXACIN; GENTAMICIN; MACROLIDE; MEROPENEM; MINOCYCLINE; PENICILLIN G; PIPERACILLIN; QUINOLONE; RIFAMPICIN; ROXITHROMYCIN; SPARFLOXACIN; STREPTOMYCIN; SULFAMETHOXAZOLE; TELITHROMYCIN; TETRACYCLINE; TICARCILLIN; TRIMETHOPRIM;

ARTICLE; BACTERIAL INFECTION; BARTONELLOSIS; BORRELIA BURGDORFERI; CAMPYLOBACTER JEJUNI; CHLAMYDIA TRACHOMATIS; CHLAMYDIAL PNEUMONIA; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; DIFFERENTIAL DIAGNOSIS; ERYTHEMA INFECTIOSUM; HUMAN; HUMAN GRANULOCYTIC ANAPLASMOSIS; LYME DISEASE; MIXED INFECTION; MYCOPLASMA PNEUMONIAE; NONHUMAN; PIROPLASMOSIS; POLYARTHRITIS; PRIORITY JOURNAL; Q FEVER; REACTIVE ARTHRITIS; RICKETTSIOSIS; TULAREMIA; YERSINIA ENTEROCOLITICA; YERSINIOSIS;

EID: 84877947042     PISSN: None     EISSN: 1874205X     Source Type: Journal    
DOI: 10.2174/1874205X01206010158     Document Type: Article

References (312)

1. Eskow E, Rao RV, Mordechai E. Concurrent infection of the central nervous system by Borrelia burgdorferi and Bartonella henselae:evidence for a noveltick-borne disease complex. Arch Neurol 2001; 58(9): 1357-1363.
2. Grab DJ, Nyarko E, Barat NC, Nikolskaia OV, Dumler JS. Anaplasma phagocytophilum-Borrelia burgdorferi co-infection enhances chemokine, cytokine, and matrix metalloprotease expression by human brainmicrovascular endothelial cells. Clin Vaccine Immunol 2007; 14(11): 1420-1424.
3. Mitchell PD, Reed KD, Hofkes JM.Immunoserologic evidence of co-infectionwith Borreliaburgdorferi, Babesia microti, and human granulocytic Ehrlichia species in residents of Wisconsin and Minnesota. J Clin Microbiol 1996; 34(3): 724-727.
4. Oleson CV, Sivalingam JJ, O'Neill BJ, Staas WE Jr. Transverse myelitis secondary to coexistent Lyme disease and babesiosis. J Spinal Cord Med 2003; 26(2): 168-171.
5. Owen DC.Is Lyme disease always poly microbial?--The jigsaw hypothesis. Med Hypotheses 2006; 67(4): 860-864.
6. Swanson SJ, Neitzel D, Reed KD, Belongia EA. Co-infections acquired from ixodes ticks. Clin Microbiol Rev 2006; 19(4): 708-727.
7. Thomas V, Anguita J, Barthold SW, Fikrig E. Co-infection with Borrelia burgdorferi and the agent of human granulocytic ehrlichiosis alters murine immune responses, pathogen burden, and severity of Lyme arthritis. Infect Immun 2001; 69(5): 3359-3371.
8. Zeidner NS, Dolan MC, Massung R, Piesman J, Fish D. Co-infection with Borrelia burgdorferi and the agent of human granulocytic ehrlichiosissuppresses IL-2 and IFN gamma production and promotes an IL-4 responsein C3H/HeJ mice. Parasite Immunol 2000; 22(11): 581-588.
9. Wormser GP, Nadelman RB, Dattwyler RJ et al. Practice guidelines for the treatment of Lyme disease.The Infectious Diseases Society of America. Clin Infect Dis 2000; 31 (Suppl) 1: 1-14.
10. Kristoferitsch W, Stanek G, Kunz C.[Double infection with early summer meningoencephalitis virus and Borrelia burgdorferi. [Article in German]. Dtsch Med Wochenschr 1986; 111(22): 861-864.
11. Hunfeld K-P. Granulocytic Ehrlichia, Babesia, and spotted fever Rickettsia. Not yet widely known tick-borne pathogens of considerableconcern forhumans at risk in Europe. Biotest Bull 2002; 6: 321-344.
12. Cadavid D, O'Neill T, Schaefer H, Pachner AR. Localization of Borrelia burgdorferi in the nervous system and other organs in a nonhuman primate model of Lyme disease. Lab Invest 2000; 80(7): 1043-1054.
13. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis,and babesiosis:clinical practice guidelines by the Infectious Diseases Societey of America. Clin Infect Dis 2006; 43(9): 1089-1134.
14. Krause PJ, Telford SR 3rd, Spielman A, et al. Concurrent Lyme disease and babesiosis.Evidence for increased severity and duration of illness. JAMA 1996; 275(21): 1657-1660.
15. Straubinger RK, Straubinger AF, Summers BA, Jacobson RH. Status of Borrelia burgdorferi infection after antibiotic treatment and the effects of corticosteroids: An experimental study. J Infect Dis 2000; 181(3): 1069-1081.
16. Stricker RB. Counterpoint:long-term antibiotic therapy improves persistent symptoms associated with lyme disease. Clin Infect Dis 2007; 45(2): 149-157.
17. Grab DJ, Nyarko E, Barat NC, Nikolskaia OV, Dumler JS. Anaplasma phagocytophilum-Borrelia burgdorferi co-infection enhances chemokine, cytokine, and matrix metalloprotease expression by human brainmicrovascular endothelial cells. Clin Vaccine Immunol 2007; 14(11): 1420-1424.
18. Bass JW, Vincent JM, Person DA. The expanding spectrum of Bartonella infections:II.Cat-scratch disease. Pediatr Infect Dis J 1997; 16(2): 163-179.
19. Spach DH, Koehler JE. Bartonella-associated infections. Infect Dis Clin North Am 1998; 12(1):137-155.
20. Wear DJ, Margileth AM, Hadfield TL, Fischer GW, Schlagel CJ, King FM.Cat scratch disease:A bacterial infection. Science 1983; 221(4618): 1403-1405.
21. Rolain JM, Foucault C, Guieu R, La Scola B, Brouqui P, Raoult D. Bartonella quintana in human erythrocytes. Lancet 2002; 360(9328): 226-228.
22. Englisch CK, Wear DJ, Margileth AM, Lissner CR, Walsh GP. Cat-scratch disease.Isolation and culture of the bacterial agent. JAMA 1988; 259(9): 1347-1352.
23. Schaller DJ. Bartonella Diagnosis and Treatment. Tampa, Florida: Hope Academic Press 2008.
24. Thudi KR, Kreikemeier TJ, Phillips NJ, Salvalaggio PR, Kennedy DJ, Hayashi PH. Cat scratch disease causing hepatic masses after liver transplant. Liver Int 2007; 27(1): 145-148.
25. Bhatti Z, Berenson CS. Adult systemic cat scratch disease associated with therapy for hepatitis C. BMC Infect Dis 2007; 7:8.
26. Koehler JE, Glaser CA, Tappero JW. Rochalimaea henselae infection.A new zoonosis with the domestic cat as reservoir. JAMA 1994; 271(7): 531-535.
27. Chomel BB, Abbott RC, Kasten RW, et al. Bartonella henselae prevalence in domestic cats in California:risk factors and association beween bacteremiaand antibody titers. J Clin Microbiol 1995; 33(9): 2445-2450.
28. Bonatti M, Mendez J, Guerrero I, et al. Disseminated Bartonella infection following liver transplantation. Transpl Int 2006; 19(8): 683-687.
29. Vannier E, Gewurz BE, Krause PJ. Human babesiosis. Infect Dis Clin North Am 2008; 22(3): 469-488.
30. Zintl A, Mulcahy G, Skerrett HE, Taylor SM, Gray JS. Babesia divergens, a bovine blood parasite of veterinary andzoonotic importance. Clin Microbiol Rev 2003; 16(4): 622-636.
31. Leiby DA. Babesiosis and blood transfusion:flying under the radar. Vox Sang 2006; 90(3): 157-165.
32. Fox LM, Wingerter S, Ahmed A, et al. Neonatal babesiosis:case report and review of the literature. Pediatr Infect Dis J 2006; 25(2): 169-173.
33. Sethi S, Alcid D, Kesarwala H, Tolan RW Jr. Probable congenital babesiosisin infant, new jersey, USA. Emerging Infect Dis 2009; 15(5): 788-791.
34. von Baehr V. The laboratory diagnostics of the Borrelia infection. Umwelt-Magazin-Gesellschaft 2/2009; 22:119-124.
35. Moriarty RA, Margileth AM. Cat-scratch disease. Infect Dis Clin North Am 1987; 1(3): 575-590.
36. Cunningham ET, Koehler JE. Ocular bartonellosis. Am J Ophthalmol 2000; 130(3): 340-9.
37. Bhatti MT, Asif R, Bhatti LB. Macular star in neuroretinitis. Arch Neurol 2001; 58(6): 1008-1009.
38. Suhler EB, Lauer AK, Rosenbaum JJ. Prevalence of serologic evidence of cat scratch disease in patients with neuroretinitis. Ophthalmology 2000; 107(5): 871-876.
39. Reed JB, Scales DK, Wong MT, Lattuada CP Jr, Dolan MJ, Schwab IR. Bartonella henselae neuroretinitis in cat scratch disease.Diagnosis,management, and sequelae. Ophthalmology 1998; 105(3): 459-466.
40. Marra CM. Neurologic complications of Bartonella henselae infection. Curr Opin Neurol 1995; 8(3): 164-169.
41. Selby G, Walker GL. Cerebral arteritis in cat-scratch disease. Neurology 1979; 29(10): 1413-1418.
42. Baylor P, Garoufi A, Karpathios T, Lutz J, Mogelof J, Moseley D. Transverse myelitis in 2 patients with Bartonella henselaeinfection (cat scratch disease). Clin Infect Dis 2007; 45(4): e42-e45.
43. Maman E, Bickels J, Ephros M, et al. Musculoskeletal manifestations of cat scratch disease. Clin Infect Dis 2007; 45(12): 1535-1540.
44. Giladi M, Maman E, Paran D, et al. Cat-scratch disease-associated arthropathy. Arthritis Rheum 2005; 52(11): 3611-3617.
45. Ben-Ami R, Ephros M, Avidor B, et al. Cat-scratch disease in elderly patients. Clin Infect Dis 2005; 41(7): 969-974.
46. th Sep 2010]
47. Jensen WA, Fall MZ, Rooney J, Kordick DL, Breitschwerdt EB. Rapididentification and differentiation of Bartonella species using a single-step PCR assay. J Clin Microbiol 2000; 38(5): 1717-1722.
48. Fournier PE, Mainardi JL, Raoult D. Value of microimmuno-fluorescence for diagnosis and follow-up of Bartonella endocarditis. Clin Diagn Lab Immunol 2002; 9(4): 795-801.
49. Ridder GJ, Boedeker CC, Technau-Ihling K, Grunow R, Sander A. Role of cat- scratch disease in lymphadenopathy in the head and neck. Clin Infect Dis 2002; 35(6): 643-649.
50. Gilaldi M, Maman E, Paran D, et al. Cat-scratch disease-associated arthropathy. Arthritis Rheum 2005; 52(11):3611-3617.
51. Ridder GJ, Boedeker CC, Technau-Ihling K. Cat-scratch disease:Otolaryngologic manifestations and management. Otolaryngol Head Neck Surg 2005; 132(3):353-358.
52. Tsujino K, Tsukahara M, Tsuneoka H, et al. Clinical implication of prolongedfever in children with cat scratch disease. J Infect Chemother 2004; 10(4): 227-233.
53. Methkor-Cotter E, Kletter Y, Avidor B, et al. Long-term serologi-cal analysis and clinical follow-up of patients with cat scratch disease. Clin Infect Dis 2003; 37(9):1149-1154.
54. Murakami K, Tsukahara M, Tsuneoka H, et al. Cat scratch disease: analysis of130 seropositive cases. J Infect Chemother 2002; 8(4): 349-352.
55. Eskow E, Rao RV, Mordechai E. Concurrent infection of the central nervous system by Borrelia burgdorferi and Bartonella henselae:evidence for a noveltick-borne disease complex. Arch Neurol 2001; 58(9):1357-1363.
56. Dietrich F, Schmidgen T, Maggi RG, et al. Prevalence of Bar-tonella henselae and Borrelia burgdorferi sensu lato DNA in ixodes ricinus ticks in Europe. Appl Environ Microbiol 2010; 76(5): 1395-1398.
57. Windsor JJ. Cat-scratch disease:epidemiology, aetiology and treatment. Br J Biomed Sci 2001; 58(2): 101-110.
58. Guptill L. Bartonellosis. Vet Microbiol 2010; 140(3-4): 357-359.
59. Cotell SL, Noskin GA. Bacillary angiomatosis.Clinical and histologic features, diagnosis, and treatment. Arch Intern Med 1994; 154(5): 524-528.
60. Pulliainen AT, Dehio C. Bartonella henselae:subversion of vascularendothelial cell functions by translocated bacterial effector proteins. Int J Biochem Cell Biol 2009; 41(3): 507-510.
61. Riess T, Andersson SG, Lupus A, et al. Bartonella adhesin mediates a proangiogenic host cell response. J Exp Med 2004; 200(10): 1267-1278.
62. Dehio C, Meyer M, Berger J, Schwarz H, Lanz C. Interaction of Bartonella henselae with endothelial cells results in bacterial aggregation on the cell surface and the subsequent engulfment and internalisation of the bacterialaggregate by a unique structure, the invasome. J Cell Sci 1997; 100(Pt 18): 2141-2154.
63. Kempf VA, Lebiedziejwski M, Alitalo K et al. Activation of hypoxia-inducible factor-1 in bacillary angiomatosis:evidence for a role of hypoxia-inducible factor-1 in bacterial infections. Circulation 2005; 111(8): 1054-1062.
64. Kirby JE. In vitro model of Bartonella henselae-induced angiogenesis. Infect Immun 2004; 72(12): 7315-7317.
65. Dehio C. Recent progress in understanding Bartonella-induced vascularproliferation. Curr Opin Microbiol 2003; 6(1): 61-65.
66. Resto-Ruiz S, Burgess A, Anderson BE. The role of the host immuneresponse in pathogenesis of Bartonella henselae. DNA Cell Biol 2003; 22(6): 431-440.
67. Kempf VA, Volkmann B, Schaller M, et al. Evidence of a leading role for VEGF in Bartonella henselae-induced endothelial cell proliferations. Cell Microbiol 2001; 3(9): 623-632.
68. Rolain JM, Amoux D, Parzy D, Sampol J, Raoult D. Experimental infection of human erythrocytes from alcoholic patients with Bartonella Quintana. Ann NYAcad Sci 2003; 990: 605-611.
69. Rolain JM, Foucault C, Guieu R, La Scola B, Brouqui P, Raoult D. Bartonella Quintana in human erythrocytes. Lancet 2002; 360(9328): 226-228.
70. Mursic VP, Wanner G, Reinhardt S, Wilske B, Busch U, Marget W. Formationand cultivation of Borrelia burgdorferi spheroplast-L-form variants. Infection 1996; 24(3): 218-226.
71. Liu NY. Randomized trial of doxycycline vs. amoxicillin/probenecid for the treatment of Lyme arthritis:treatment of non responders with iv penicillin or ceftriaxone. Arthritis Rheum 1989; 32: 46.
72. Kraiczy P, Skerka C, Kirschfink M, Zipfel PF, Brade V. Immune evasion of Borrelia burgdorferi:insufficient killing of the pathogens by complement and antibody. Int J Med Microbiol 2002; 291 (Suppl 33): 141-146.
73. Kraiczy P, Skerka C, Zipfel PF, Brade V. Complement regulator-acquiring surface proteins of Borrelia burgdorferi:a new protein family involved in complement resistance. Wien Klin Wochenschr 2002; 114(13-14): 568-573.
74. Mursic VP, Wanner G, Reinhardt S, Wilske B, Busch U, Marget W. Formationand cultivation of Borrelia burgdorferi spheroplast-L-form variants. Infection 1996; 24(3): 218-226.
75. Brorson O, Brorson SH. An in vitro study of the susceptibility of mobile andcystic forms of Borrelia burgdorferi to hydroxychloroquine. Int Microbiol 2002; 5(1): 25-31.
76. Kerkhoff FT, Rothova A. Bartonella henselae associated uveitis and HLA-B27. Br J Ophthalmol 2000; 84(10): 1125-1129.
77. Foucault C, Brouqui P, Raoult D. Bartonella quintana characteristics and clinical management. Emerg Infect Dis 2006; 12(2): 217-223.
78. Relman DA. Has trench fever returned? N Engl J Med 1995; 332(7): 463-464.
79. Vinson JW. In vitro cultivation of the rickettsial agent of trench fever. Bull World Health Organ 1966; 35(2): 155-164.
80. Spach DH, Kanter AS, Dougherty MJ, et al. Bartonella (Rochalimaea) quintana bacteremia in inner-city patients with chronic alcoholism. N Engl J Med 1995; 332(7): 424-428.
81. Bass JW, Freitas BC, Freitas AD, et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J 1998; 17(6): 447-452.
82. Study Team. Atovaquone plus cholestyramine in patients coinfected with Babesia microti and Borrelia burgdorferi refractory to othertreatment. Adv Ther 2006; 23(1): 1-11.
83. Chia JK, Nakata MM, Lami JL, Park SS, Ding JC. Azithromycin for the treatment of cat-scratch disease. Clin Infect Dis 1998; 26(1): 193-194.
84. Arisoy ES, Correa AG, Wagner ML, Kaplan SL. Hepatosplenic cat-scratch disease in children:selected clinical features and treatment. Clin Infect Dis 1999; 28(4): 778-784.
85. Bogue CW, Wise JD, Gray GF, Edwards KM.Antibiotic therapy for cat-scratch disease? JAMA 1989; 262(6): 813-816.
86. Foucault C, Raoult D, Brouqui P. Randomized open trial of gentamicin and doxycycline for eradication of Bartonella quintana from blood in patients with chronic bacteremia. Antimicrob Agents Chemother 2003; 47(7): 2204-2207.
87. Raoult D, Fournier PE, Vandenesch F, et al. Outcome and treatment of Bartonella endocarditis. Arch Intern Med 2003; 163(2): 226-230.
88. Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 2004; 48(6): 1921-1933.
89. Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Minireview. Recommendations for Treatment of Human Infections Caused by Bartonella Species. Antimicrob Agents Chemother 2004; 1921-1933.
90. Pendle S, Ginn A, Iredell J. Antibicrobial susceptibility of Bar-tonella henselae using Etest methodology. Antimicrob Agents Che-mother 2006; 761-763.
91. Dörbecker C, Sander A, Oberle K, Schülin-Casonato T. In vitro susceptivility of Bartonella species in 17 antimicrobial compounds: comparison of Etest and agar dilution. Antimicrob Agents and Chemotherapy 2006; 784-788.
92. Florin TA, Zaoutis TE, Zaoutis LB. Beyond cat scratch disease: widening spectrum of Bartonella henselae infektion. Pediatrics 2008; 121; e1413.
93. Tsuneoka H, Yanagihara M, Nojima J, Ichihara K. Anitmicrobial susceptibility by Etest of Bartonella henselae isolated from cats and human in Japan. J Infect Chemother 2010; 16(6): 446-448
94. Conrad DA. Treatment of cat-scratch disease. J Curr Opin Pediatr 2001; 13(1): 56-59.
95. Sander A. Epidemiology, clinic picture und diagnostics of Bar-tonella infections. Institute for Medical Microbiology and Hygiene of the University of Freiburg. Antibiotika Monitor 2003. vol.3,
96. Sobraqués M, Maurin M, Birtels RJ, Raoult D. In Vitro Susceptibilities of Four Bartonella bacilliformis Strains to 30 Antibiotic Compounds. Antimicrob Agents Chemother 1999; 43(8): 2090-2092.
97. Rolain JM, Maurin M, Raoult D. Bactericidal effect of antibiotics on Bartonella and Brucella spp.: clinical implications. J Antimicrob Chemother 2000; 46(5):811-814.
98. Margileth AM. Antibiotic therapy for cat-scratch disease:clinical study of therapeutic outcome in 268 patients and a review of the literature. Pediatr Infect Dis J 1992; 11(6): 474-478.
99. Musso D, Drancourt M, Raoult D. Lack of bactericidal effect of antibiotics except aminoglycosides on Bartonella (Rochalimaea) henselae. Br Soc Antimicrob Chemother 1995; 36: 101-108.
100. Biswas S, Maggi RC, Papich MG, Keil D, Breitschwerdt EB. Comparative activity of Pradofloxacin, Enrofloxacin, And Azithromycin against Bartonella henselae isolates collected from cats and a human. J Clin Microbiol 2010; 617-618.
101. Ives TJ, Manzewitsch P, Regnery RL, Butts JD, Kebede M. In vitro susceptibilities of Bartonella henselae, B. quintana, B. elizabethae, Rickettsia rickettsii, R. conorii, R. akari, and R. prowazekii to mac-rolide antibiotics as determined by immunofluorescent-antibody analysis of infected Vero cell monolayers. Antimicrob Agents Chemother 1997; 41(3): 578-582.
102. Musso D, Drancourt M, Raoult D. Lack of bactericidal effect of antibiotics except aminoglycosides on Bartonella (Rochalimaea) henselae. J Antimicrob Chemother 1995; 36(1):101-108.
103. Kordick DL, Papich MG, Breitschwerdt EB. Efficacy of enroflox-acin or doxycycline for treatment of Bartonella henselae or Bar-tonella clarridgeiae infection in cats. Antimicrob Agents Chemo-ther 1997; 41(11): 2448-2455.
104. Kordick DL, Papich MG, Breitschwerdt EB. Efficacy of Enroflox-acin or Doxycycline for Treatment of Bartonella henselae or Bar-tonella clarridgeiae Infection in Cats. Antimicrob Agents Chemo-ther 1997; 41(11): 2448-2455.
105. Madell, GL, Bennett, JE, Dolin, R, Eds. Infectious Diseases 5th ed, Philadelphia: Churchill Livingstone 2000, p. 2007.
106. Myhra W, Mordhorst CH, Wang SP, et al. Clinical features of Chlamydia pneumoniae, strain TWAR, infection in Denmark 1975-1987. In: Bowie, WR, Caldwell, HD, Jones, RP (Eds), Chlamydial Infections. Cambridge Univ. Press, NY: 1980, p. 422.
107. Bourke SJ, Lightfoot NF. Chlamydia pneumoniae:defining the clinicalspectrum of infection requires precise laboratory diagnosis. Thorax 1995; 50(Suppl 1):S43-S48.
108. Carter JD, Espinoza LR, Inman RD, et al. Combination antibiotics as atreatment for chronic Chlamydia-induced reactive arthritis:a double-blind,placebo-controlled, prospective trial. Arthritis Rheum 2010; 62(5): 1298-1307.
109. Gérard HC, Whittum-Hudson JA, Carter JD, Hudson AP. Molecular biology of infectious agents in chronic arthritis. Rheum Dis Clin North Am 2009; 35(1): 1-19.
110. Carter JD, Gérard HC, Espinoza LR, et al. Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis. Arthritis Rheum 2009; 60(5): 1311-1316.
111. Fainardi E, Castellazzi M, Tamborino C, et al. Chlamydia pneu-moniae-specific intrathecal oligoclonal antibody response is predominantly detected in asubset of multiple sclerosis patients with progressive forms. J Neurovirol 2009; 15(5-6): 425-433.
112. Appelt DM, Roupas MR, Way DS, et al. Inhibition of apoptosis in neuronal cells infected with Chlamydophila (Chlamydia) pneumoniae. BMC Neurosci 2008; 9: 13.
113. Contini C, Cultrera R, Seraceni S, Castellazzi M, Granieri E, Fainardi E. Cerebrospinal fluid molecular demonstration of Chla-mydia pneumoniae DNAis associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing-remitting multiple sclerosis. Mult Scler 2004; 10(4): 360-369.
114. Gerard HC, Wang Z, Whittum-Hudson JA, et al. Cytokine and chemokine mRNA produced in synovial tissue chronically infected with Chlamydia trachomatis and C. pneumoniae. J Rheumatol 2002; 29(9): 1827-1835.
115. De Backer J, Mak R, De Bacquer D, et al. Parameters of inflammation and infection in a community based case-control study of coronary heart disease. Atherosclerosis 2002; 160(2): 457-463.
116. Miklossy J, Kasas S, Zum AD, McCall S, Yu S, McGeer PL. Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosis. J Neuroinflammation 2008; 5: 40.
117. Almeida OP, Lautenschlager NT. Dementia associated with infectious diseases. Int Psychogeriatr 2005; 17 (Suppl 1):S65-S77.
118. MacDonald AB. Alzheimer's disease Braak Stage progressions: reexamined and redefined as Borrelia infection transmission through neural circuits. Med Hypotheses 2007; 68(5): 1059-1064.
119. Fallon BA, Levin ES, Schweitzer PJ, Hardesty D. Inflammation and central nervous system Lyme disease. Neurobiol Dis 2010; 37(3): 534-541.
120. Tuuminen T, Palomäki P, Paavonen J. The use of serologic tests for thediagnosis of chlamydial infections. J Microbiol Methods 2000; 42(3): 265-279.
121. Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae:current status of diagnostic methods. Clin Infect Dis 2007; 44(4): 568-576.
122. Gaydos CA, Roblin PM, Hammerschlag MR, et al. Diagnostic utility of PCR- enzyme immunoassay, culture, and serology for detection of Chlamydia pneumoniae in symptomatic and asymptomatic patients. J Clin Microbiol 1994; 32(4): 903-905.
123. Vergis EN, Indorf A, File TM Jr, et al. Azithormycin vs cefu-roxime plus erythromycin for empiricaltreatment of community-acquired pneumonia in hospitalized patients:a prospective, randomized, multicenter trial. Arch Intern Med 2000; 160(9): 1294-1300.
124. st century:areview of gemifloxacin. Int J Antimicrob Agents 2004; 23(6): 533-546.
125. Villareal C, Whittum-Hudson JA, Hudson AP.Persistent Chlamydiae and chronic arthritis. Arthritis Res 2002; 4(1): 5-9.
126. Beutler AM, Hudson AP, Whittum-Hudson JA, et al. Chlamydia trachomatis Can Persist in Joint Tissue After Antibiotic Treatment in Chronic Reiter'sSyndrome/Reactive Arthritis. J Clin Rheumatol 1997; 3(3): 125-130.
127. Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55(RR-11): 1-94.
128. Quinn TC, Welsh L, Lentz A, et al. Diagnosis by AMPLICOR PCR of Chlamydia trachomatis infection in urine samples from women and men attending sexually transmitted disease clinics. J Clin Microbiol 1996; 34(6): 1401-1406.
129. Chernesky MA, Lee H, Schachter J, et al. Diagnosis of Chlamydia trachomatis urethral infection insymptomatic and asymptomatic men by testing first-voidurine in a ligase chain reaction assay. J Infect Dis 1994; 170(5): 1308-1311.
130. Cook RL, Hutchinson SL. Ostergaard L, Braithwaite RS, Ness RB.Systematic review:noninvasive testing for Chlamydia trachomatis and Neisseriagonorrhea. Ann Intern Med 2005; 142(11): 914-925.
131. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39(12): 2021-2027.
132. Flagg SD, Meador R, Hsia E, Kitumnuaypong T, Schumacher HR Jr. Decreased pain and synovial inflammation after etanercept therapy in patientswith reactive and undifferentiated arthritis:an open-label trial. Arthritis Rheum 2005; 53(4): 613-617.
133. Ostroff S. Yersinia as an emerging infection:epidemiologic aspects ofYersiniosis. Contrib Microbiol Immunol 1995; 13: 5-10.
134. Portnoy DA, Martinez RJ. Role of a plasmid in the pathogenicity of Yersinia species. Curr Top Microbiol Immunol 1985; 118: 29-51.
135. Iriarte M, Sory MP, Boland A, et al. TyeA, a protein involved in control of Yop release and in translocation of Yersinia Yop effectors. EMBO J 1998; 17(7): 1907-1918.
136. Sarker MR, Sory MP, Boyd AP, Iriarte M, Comelis GR. LcrG is required for efficient translocation of Yersinia Yop effector proteins into eukaryotic cells. Infect Immun 1998; 66(6): 2976-2979.
137. Boland A, Cornelis GR. Role of YopP in suppression of tumor necrosis factoralpha release by macrophages during Yersinia infection. Infect Immun 1998; 66(5): 1878-1884.
138. Tacket CO, Narain JP, Sattin R, et al. A multistate outbreak of infections caused by Yersiniaenterocolitica transmitted by pasteurized milk. JAMA 1984; 251(4): 483-486.
139. Ostroff SM, Kapperud G, Lassen J, Aasen S, Tauxe RV. Clinical features ofsporadic Yersinia enterocolitica infections in Norway. J Infect Dis 1992; 166(4): 812-817.
140. Tauxe RV, Vandepitte J, Wauters G, et al. Yersinia enterocolitica infections and pork:the missing link. Lancet 1987; 1(8542): 1129-1132.
141. Tacket CO, Davis BR, Carter GP, Randolph JF, Cohen ML. Yersinia enterocolitica pharyngitis. Ann Intern Med 1983; 99(1): 40-42.
142. Cover TL, Aber RC. Yersinia enterocolitica. N Engl J Med 1989; 321(1): 16-24.
143. Black RE, Slome S. Yersinia enterocolitica. Infect Dis Clin North Am 1988; 2(3): 625-641.
144. Reed RP, Robins-Browne RM, Williams ML.Yersinia enterocolitica peritonitis. Clin Infect Dis 1997; 25(6): 1468-1469.
145. Blinkhorn RJ Jr, Marino JA. Lateral pharyngeal abscess due to Yersinia enterocolitica. Am J Med 1988; 85(6): 851-852.
146. Krogstad P, Mendelman PM, Miller VL, et al. Clinical and micro-biologic characteristics of cutaneuous infection with Yersinia enterocolitica. J Infect Dis 1992; 165(4): 740-743.
147. Crowe M, Ashford K, Ispahani P. Clinical features and antibiotic treatment ofseptic arthritis and osteomyelitis due to Yersinia enterocolitica. J Infect Microbiol 1996; 45(4): 302-309.
148. Kellogg CM, Tarakji EA, Smith M, Brown PD. Bacteremia and suppurative lymphadenitis due to Yersinia enterocolitica in a neutropenic patient who prepared chitterlings. Clin Infect Dis 1995; 21(1): 236-237.
149. Saebo A, Lassen J. Yersinia enterocolitica:an inducer of chronic inflammation. Int J Tissue React 1994; 16(2): 51-57.
150. Saebo A, Lassen J. Acute and chronic pancreatic disease associated withYersinia enterocolitica infection:a Norwegian 10-year follow-up study of 458hospitalized patients. J Intern Med 1992; 231 (5): 537-41.
151. Saebo A, Lassen J. Acute and chronic gastrointestinal manifestationsassociated with Yersinia enterocolitica infection. A Norwegian 10-year follow-up study on 458 hospitalized patients. Ann Surg 1992; 215(3): 250-255.
152. Lindholm H, Visakorpi R. Late complications after a Yersinia enterocolitica epidemic:a follow up study. Ann Rheum Dis 1991; 50(10): 694-696.
153. Saebo A, Lassen J. A survey of acute and chronic disease associated with Yersinia enterocolitica infection. A Norwegian 10-year follow-up study on 458 hospitalized patients. Scand J Infect Dis 1991; 23(5): 517-527.
154. Fordham JN, Maitra S. Post-yersinial arthritis in Cleveland, England. Ann Rheum Dis 1989; 48(2): 139-142.
155. Saebo A, Vik E, Lange OJ, Matuszkiewicz L. Inflammatory bowel disease associated with Yersinia enterocolitica O:3 infection. Eur J Intern Med 2005; 16(3): 176-182.
156. van der Heijden IM, Res PC, Wilbrink B, et al. Yersinia enterocoli-tica: a causeof chronic polyarthritis. Clin Infect Dis 1997; 25(4): 831-837.
157. Granfors K, Jalkanen S, von Essen R, et al. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. N Engl J Med 1989; 320(4): 216-221.
158. Granfors K, Merilahti-Palo R, Luukkainen R, et al. Persistence of Yersinia antigens in peripheral blood cells from patients with Yersinia enterocolitica O:3 infection with or without reactivearthritis. Arthritis Rheum 1998; 41(5): 855-862.
159. Leirisalo-Repo M, Suoranta H. Ten-year follow-up study of patient with Yersinia arthritis. Arthritis Rheum 1988; 31(4): 533-537.
160. Braun J, Tuszewski M, Eggens U, et al. Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial speciesin inflammatory joint diseases. I. Screening of synovial samples of patients with spondyloarthropathies and other arthritides. J Rheumatol 1997; 24(6): 1092-1100.
161. Hoogkamp-Korstanje JA, de Koning J, Heesemann J. Persistence of Yersinia enterocolitica in man. Infection 1988; 16(2): 81-85.
162. Bottone EJ. Yersinia enterocolitica:the charisma continues. Clin Microbiol Rev 1997; 10(2): 257-276.
163. Martin RE, Bates JH. Atypical pneumonia. Infect Dis Clin North Am 1991; 5(3): 585-601.
164. Frydén A, Bengtsson A, Foberg U, et al. Early antibiotic treatment of reactive arthritis associated with enteric infections:clinical and serological study. BMJ 1990; 301(6764): 1299-1302.
165. Mansel JK, Rosenow EC 3rd, Smith TF, Martin JW Jr. Mycoplasma pneumoniae pneumonia. Chest 1989; 95(3): 639-646.
166. Koskiniemi M. CNS manifestations associated with Mycoplasma pneumoniae infections:summary of cases at the University of Helsinki and review. Clin Infect Dis 1993; 17 (Suppl 1):S52-S57.
167. Daxboeck F. Mycplasma pneumoniae central nervous system infections. Curr Opin Neurol 2006; 19(4): 374-378.
168. Bitnun A, Ford-Jones E, Blaser S, Richardson S. Mycoplasma pneumoniae encephalitis. Semin Pediatr Infect Dis 2003; 14(2): 96-107.
169. Smith R, Eviatar L. Neurologic manifestations of Mycoplasma pneumoniae infections:diverse spectrum of diseases.A report of six cases and review ofthe literature. Clin Pediatr (Phila) 2000; 39(4): 195-201.
170. Tsiodras S, Kelesidis T, Kelesidis I, Voumbourakis K, Giamarellou H. Mycoplasma pneumoniae-associated myelitis:a comprehensive review. Eur J Neurol 2006; 13(2): 112-124.
171. Chaudhry R, Nisar N, Malhotra P, Kumar A, Chauhan VS. Polymerase chain reaction confirmed Mycoplasma pneumoniae arthritis:a case report. Indian J Pathol Microbiol 2003; 46(3): 433-643.
172. Vitullo BB, O'Regan S, de Chadarevian JP, Kaplan BS. Mycoplasmapneumonia associated with acute glomerulonephritis. Nephron 1978; 21(5): 284-288.
173. Weinstein O, Shneck M, Levy J, Lifshitz T. Bilateral acute anterior uveitis as a presenting symptom of Mycoplasma pneumoniae infection. Can J Ophthalmol 2006; 41(5): 594-595.
174. Yashar SS, Yashar B, Epstein E, Viani RM. Uveitis associated withMycoplasma pneumoniae meningitis. Acta Ophthalmol Scand 2001; 79(1): 100-101.
175. Fusco C, Bonini E, Soncini G, Frattini D, Giovannini S, Della Giustina E. Transient basal ganglia and thalamic involvement following Mycoplasma pneumoniae infection associated with antiganglioside antibodies. J Child Neurol 2010; 25(8): 1029-1033.
176. Ashtekar CS, Jaspan T, Thomas D, Weston V, Gayatri NA, Whitehouse WB.Acute bilateral thalamic necrosis in a child with Mycoplasma pneumoniae. Dev Med Child Neurol 2003; 45(9): 634-637.
177. Hsing J, Welgampola M, Kieman MC. Reversible myeloradicu-lopathy due to Mycoplasma pneumoniae. J Clin Neurosci 2007; 14(1): 61-64.
178. Tsiodras S, Kelesidis I, Kelesidis T, Stamboulis E, Gimarellou H. Central nervous system manifestations of Mycoplasma pneumoniae infections. J Infect 2005; 51(5): 343-354.
179. Timitilli A, Di Rocco M, Nattero G, Tacchella A, Giacchino R. Unusual manifestations of infections due to Mycoplasma pneumoniae in children. Infez Med 2004; 12(2): 113-117.
180. Goebels N, Helmchen C, Abele-Horn M, Gasser T, Pfister HW.Extensive myelitis associated with Mycoplasma pneumoniae infection:magneticresonance imaging and clinical long-term follow-up. J Neurol 2001; 248(3): 204-208.
181. Rabay-Chacar H, Rizkallah E, Hakimeh NI, Khoury L, Merhej MT. Neurological complications associated with Mycoplasma pneumo-niae infection.A case report. J Med Liban 2000; 48(2): 108-111.
182. Abele-Horn M, Franck W, Busch U, Nitschko H, Roos R, Heesemann J. Transverse myelitis associated with Mycoplasma pneumoniae infection. Clin Infect Dis 1998; 26(4): 909-912.
183. Francis DA, Brown A, Miller DH, Wiles CM, Bennett ED, Leigh N. MRI appearances of the CNS manifestations of Mycoplasma pneumoniae:a reportof two cases. J Neurol 1988; 235(7): 441-443.
184. MacFarlane PI, Miller V. Transverse myelitis associated with Mycoplasma pneumoniae infection. Arch Dis Child 1984; 59(1): 80-82.
185. Cotter FE, Bainbridge D, Newland AC. Neurological deficit associated with Mycoplasma pneumoniaereversed by plasma exchange. Br Med J (Clin ResEd) 1983; 286(6358): 22.
186. Nicholson G. Transverse myelitis complicating Mycoplasma pneumoniae infection. Postgrad Med J 1977; 53(616): 86-87.
187. Hely MA, Williamson PM, Terenty TR. Neurological complications ofMycoplasma pneumoniae infection. Clin Exp Neurol 1984; 20: 153-160.
188. Gorthi SP, Kapoor L, Chaudhry R, et al. Guillain-Barré syndrome:associationwith Campylobacter jejuni and Mycoplasma pneumoniae infections in India. Natl Med J India 2006; 19(3): 137-139.
189. Manteau C, Liest JM, Caillon, J et al. Acute severe spinal cord dysfunction in a child with meningitis: Streptococcus pneumoniae and Mycoplasmapneumoniae co-infection. Acta Paediatr 2005; 94(9): 1339-1341.
190. Pfausler B, Engelhardt K, Kampfl A, Spiss H, Tafemer E, Schmutzhard E. Post-infectious central and peripheral nervous system diseases complicatingMycoplasma pneumoniae infection.Report of three cases and review of theliterature. Eur J Neurol 2002; 9(1): 93-96.
191. Van Koningsveld R, Van Doom PA, Schmitz PI, Ang CW, Van der Meché FG. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands. Neurology 2000; 54(3): 620-625.
192. Maida E, Kristoferitsch W. Cerebrospinal fluid findings in mycoplasma pneumoniae infections with neurological complications. Acta Neurol Scand 1982; 65(5): 524-538.
193. Bayer AS, Galpin JE, Theofilopoulos AN, Guze LB. Neurological disease associated with Mycoplasma pneumoniae pneumonitis: demonstration of viable Mycoplasma pneumoniaein cerebrospinal fluid and blood byradioisotopic and immunofluorescent tissueculture techniques. Ann Intern Med 1981; 94(1): 15-20.
194. Socan M, Ravnik I, Bencina D, Dovc P, Zakotnik B, Jazbec J. Neurological symptoms in patients whose cerebrospinal fluid is culture- and/or polymerasechain reaction-positive for Mycoplasma pneumoniae. Clin Infect Dis 2001; 32(2): E31-E35.
195. Dionisio D, Valassina M, Mata S, et al. Encephalitis caused directly by Mycoplasma pneumoniae. Scand J Infect Dis 1999; 31(5): 506-509.
196. Narita M, Matsuzono Y, Itakura O, Togashi T, Kikuta H. Survey ofmycoplasmal bacteremia detected in children by polymerase chain reaction. Clin Infect Dis 1996; 23(3): 522-525.
197. Thomas NH, Collins JE, Robb SA, Robinson RO. Mycoplasma pneumoniae infection and neurologicaldisease. Arch Dis Child 1993; 69(5): 573-576.
198. Carstensen H, Nilsson KO. Neurological complications associated withMycoplasma pneumoniae infection in children. Neuropediatrics 1987; 18(1): 57-58.
199. Foy HM, Nolan CM, Allan ID. Epidemiologic aspects of M. pneumoniae disease complications:a review. Yale J Biol Med 1983; 56(5-6): 469-473.
200. Mardh PA, Ursing B, Lind K. Persistent cerebellar symptoms after infectionwith Mycoplasma pneumoniae. Scand J Infect Dis 1975; 7(2): 157-160.
201. Trad S, Ghosn J, Dormont D, Stankoff B, Bricaire F, Caumes E. Nuclear bilateral Bell's palsy and ageusia associated with Mycoplasma pneumoniaepulmonary infection. J Med Microbiol 2005; 54(Pt4): 417-4119.
202. Völter C, Helms J, Weissbrich B, Rieckmann P, Abele-Horn M. Frequent detection of Mycoplasma pneumoniae in Bell's palsy. Eur Arch Otorhinolaryngol 2004; 261(7): 400-404.
203. Koskiniemi M. CNS manifestations associated with Mycoplasma pneumoniae infections:summary of cases at the University of Helsinki and review. Clin Infect Dis 1993; 17 (Suppl) 1:S52-S57.
204. Assaad F, Gispen R, Kleemola M, Syrucek L, Esteves K. Neurologicaldiseases associated with viral and Mycoplasma pneumoniae infections. Bull World Health Organ 1980; 58(2): 297-311.
205. Lind K, Zoffmann H, Larsen SO, Jessen O. Mycoplasma pneumoniaeinfection associated with affection of the central nervous system. Acta Med Scnad 1979; 205(4): 325-332.
206. Fink CG, Sillis M, Read SJ, Butler L, Pike M. Neurological disease associatedwith Mycoplasma pneumoniae infection. PCR evidence against a directinvasive mechanism. Clin Mol Pathol 1995; 48(1): M51-M54.
207. Di Maria A, Ruberto G, Redaelli C, Gualtieri G. Anterior uveitis associated with Mycoplasma pneumoniaepneumonia:a case report. Acta Ophthalmol Scand 1999; 77(3): 349-350.
208. Said MH, Layani MP, Colon S, Faraji G, Gilastre C, Cochat P. Mycoplasma pneumoniae-associated nephritis in children. Pediatr Nephrol 1999; 13(1): 39-44.
209. Schonwald S, Gunjaca M, Kolacny-Babic L, Car V, Gosev M. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimocrob Chemother 1990; 25 (Suppl) A: 123-126.
210. File TM Jr, Segreti J, Dunbar L, et al. A mulicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacinversus ceftriaxone and/or cefuroxime axetil in treatment of adults withcommunity-acquired pneumonia. Antimicrob Agents Chemother 1997; 41(9): 1965-1972.
211. Maeda K, Markowitz N, Hawley RC, Ristic M, Cox D, McDade JE.Human infection with Ehrlichia canis, a leukocytic rickettsia. N Engl J Med 1987; 316(14): 853-856.
212. Chen SM, Dumler JS, Bakken JS, Walker DH. Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease. J Clin Microbiol 1994; 32(3): 589-595.
213. Nadelman RB, Horowitz HW, Hsieh TC, et al. Simultaneous humangranulocytic ehrlichiosis and Lyme borreliosis. N Engl J Med 1997; 337(1): 27-30.
214. Schwartz I, Fish D, Daniels TJ. Prevalence of the rickettsial agent of human granulocytic ehrlichiosis in ticks from a hyperendemic focus of Lyme disease. N Engl J Med 1997; 337(1): 49-50.
215. Horowitz HW, Kilchevsky E, Haber S, et al. Perinatal transmission of the agent of human granulocytic ehrlichiosis. N Engl J Med 1998; 339(6): 375-378.
216. Bakken JS, Dumler S. Human granulocytic anaplasmosis. Infect Dis Clin North Am 2008; 22(3): 433-448.
217. Bakken JS, Krueth JK, Lund T, Malkovitch D, Asanovich K, Dumler JS. Exposure to deer blood may be a cause of human granulocytic ehrlichiosis. Clin Infect Dis 1996; 23(1): 198.
218. Krause PJ, Wormser GP. Nosocomial transmission of human granulocytic anaplasmosis? JAMA 2008; 300(19): 2308-2309.
219. Levin ML, Fish D. Acquisition of co-infection and simultaneous transmission of Borrelia burgdorferi and Ehrlichia phagocytophila by Ixodes scapularis ticks. Infect Immun 2000; 68(4): 2183-2186.
220. Maeda K, Markowitz N, Hawley RC, Ristic M, Cox D, McDade JE. Humaninfection with Ehrlichia canis, a leukocytic rickettsia. N Engl J Med 1987; 316(14): 853-856.
221. Chen SM, Dumler JS, Bakken JS, Walkder DH. Identification of agranulocytotrophic ehrlichia species as the etiologic agent of human disease. J Clin Microbiol 1994; 32(3): 589-595.
222. Demma LJ, Holman RC, McQuiston JH, Krebs JW, Swerdlow DL.Epidemiology of human ehrlichiosis and anaplasmosis in the United States, 2001-2001. Am J Trop Med Hyg 2005; 73(2): 400-409.
223. Björsdorff A, Wittesjö B, Berglun J, Massung RF, Eliasson I. Humangranulocytic ehrlichiosis as a common cause of tick-associated fever in Southeast Sweden:report from a prospective clinical study. Scand J Infect Dis 2002; 34(3): 187-191.
224. Stanczak J, Gabre RM, Kruminis-Lozowska W, Racewicz M, Kubica-Biemat B. Ixodes ricinus as a vector of Borrelia burgdorferi sensu lato, Anaplasma phagocytophilum and Babesia microti in urban and suburban forests. Ann Agric Environ Med 2004; 11(1): 109-114.
225. Fingerle V, Munderloh UG, Liegl G, Wilske B. Coexistence of ehrlichiae of the phagocytophila group with Borrelia burgdorferi in Ixodes ricinus from Southern Germany. Med Microbiol Immunol 1999; 188(3): 145-149.
226. Oehme R, Hartelt K, Backe H, Brockmann S, Kimming P. Foci of tick-borne diseases in southwest Germany. Int J Med Microbiol 2002; 291 (Suppl) 33: 22-29.
227. Schouls LM, Van De Pol I, Rijpkema SG, Schot CS. Detection andidentification of Ehrlichia, Borrelia burgdorferisensu lato, and Bartonellaspecies in Dutch Ixodes ricinus ticks. J Clin Microbiol 1999; 37(7): 2215-2222.
228. Baumgarten B, Harrer TH, Röllinghoff M, Bogdan C. Prevalence of human granulocytic Ehrlichiosis in Ixodes ticks from Southern Germany:Evidence for genetic heterogenety. VIII International Conference on Lyme disease and other Emerging Tick-Borne Diseases, Munich, 1999 (abstract).
229. Hildebrandt A, Schmidt KH, Wilske B, Dom W, Straube E, Fingerle V. Prevalence of four species of Borrelia burgdorferi sensu lato and co-infection with Anaplasma phagocytophila in Ixodes ricinus ticks in central Germay. Eur J Clin Microbiol Infect Dis 2003; 22(6): 364-367.
230. Schauber EM, Gertz SJ, Maple WT, Ostfeld RS. Co-infection of blackleggedticks (Acari:Ixodidae) in Dutchess County, New York, with the agents of Lymedisease and human granulocytic ehrlichiosis. J Med Entomol 1998; 35(5): 901-903.
231. Schwartz I, Fish D, Daniels TJ. Prevalence of the rickettsial agent of human granulocytic ehrlichiosis in ticks from a hyperendemic focus of Lyme disease. N Engl J Med 1997; 337(1): 49-50.
232. Bakken JS, Krueth J, Tilden RL, Dumler JS, Kristiansen BE. Serological evidence of human granulocytic ehrlichiosis in Norway. Eur J Microbiol Infect Dis 1996; 15(10): 829-832.
233. Hermanowska-Szpakowicz T, Skotarczak B, Kondrusik M, et al. Detecting DNAs of Anaplasma phagocytophilum and Babesia in the blood of patients suspected of Lyme- disease. Ann Agric Environ Med 2004; 11(2): 351-354.
234. Pusterla N, Weber R, Wolfensberger C, et al. Serological evidence of human granulocytic ehrlichiosis in Switzerland. Eur J Clin Microbiol Infect Dis 1998; 17(3): 207-209.
235. Magnarelli LA, Dumler JS, Anderson JF, Johnson RC, Fikring E. Coexistenceof antibodies to tick-borne pathogenes of babesiosis, ehrlichiosis, and Lymeborreliosis in human sera. J Clin Microbiol 1995; 33(11): 3054-3057.
236. Bakken JS, Dumler S. Human granulocytic anaplasmosis. Infect Dis Clin North Am 2008; 22(3): 433-448.
237. Roland WE, McDonald G, Caldwell CW, Everett ED. Ehrlichiosis - a cause of prolonged fever. Clin Infect Dis 1995; 20(4): 821-825.
238. Aguero-Rosenfeld ME, Horowitz HW, Wormser GP, et al. Human granulocytic ehrlichiosis:A case series from a medical center in New York State. Ann Intern Med 1996; 125(11): 904-908.
239. Bakken JS, Dumler JS. Clinical diagnosis and treatment of human granulocytotropic anaplasmosis. Ann N Y Acad Sci 2006; 1078: 236-247.
240. Dumler JS, Bakken JS. Ehrlichial diseases of humans:emerging tick-borne infections. Clin Infect Dis 1995; 20(5): 1102-1110.
241. Dawson JE, Fishbein DB, Eng TR, Redus MA, Green NR. Diagnosis of human ehrlichiosis with the indirect fluorescentantibody test:kinetics and specificity. J Infect Dis 1990; 162(1): 91-95.
242. Brouqui P, Bacellar F, Baranton G, et al. Guidelines for the diagnosis of tick-borne bacterial diseases in Europe. Clin Microbiol Infect 2004; 10(12): 1108-1132.
243. Bakken JS, Haller I, Riddell D, Walls JJ, Dumler JS. The serological responseof patients infected with the agent of human granulocytic ehrlichiosis. Clin Infect Dis 2002; 34(1): 22-27.
244. Bakken JS, Dumler JS. Ehrlichiosis and anaplasmosis. Infect Med 2004; 21:433.
245. Paddock CD, Childs JE. Ehrlichia chaffeensis:a prototypical emergingpathogen. Clin Microbiol Rev 2003; 16(1): 37-64.
246. Bakken JS, Krueth J, Wilson-Nordskog C, Tilden RL, Asanovich K, Dumler JS. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA 1996; 275(3): 199-205.
247. Bakken JS, Aguero-Rosenfeld ME, Tilden RL, et al. Serial measurements of hematologic counts during the active phase of human granulocyticehrlichiosis. Clin Infect Dis 2001; 32(6): 862-870.
248. Chapman AS, Bakken JS, Folk SM, et al. Diagnosis and management oftickborne rickettsial diseases:Rocky Mountain spotted fever, ehrlichiosis, andanaplasmosis - United States:a pracitcal guide for physicians and otherhealth-care and public health professionals. MMWR Recomm Rep 2006; 55(RR-4): 1-27.
249. Standaert SM, Yu T, Scott MA, et al. Primary isolation of Ehrlichia chaffeensis from patients with febrile illnesses:clinical and molecular characteristics. J Infect Dis 2000; 181(3): 1082-1088.
250. Felek S, Unver A, Stich RW, Rikihisa Y. Sensitive detection of Ehrlichia chaffeensis in cell culture, blood, and tick specimens by reverse transcription-PCR. J Clin Microbiol 2001; 39(2): 460-463.
251. Walls JJ, Caturegli P, Bakken JS, Asanovich KM, Dumler JS. Improvedsensitivity of PCR for diagnosis of human granulocytic ehrlichiosis usingepank1 genes of Ehrlichia phagocytophila-group ehrlichiae. J Clin Microbiol 2000; 38(1): 354-356.
252. Meer-Scherrer L, Adelson M, Mordechai E, Lottaz B, Tilton R. Babesia microti infection in Europe. Curr Microbiol 1996; 48(6): 435-437.
253. Mitchell PD, Reed KD, Hofkes JM. Immunoserologic evidence of co-infectionwith Borreliaburgdorferi, Babesia microti, and human granulocytic Ehrlichia species in residents of Wisconsin and Minnesota. J Clin Microbiol 1996; 34(3): 724-727.
254. Oleson CV, Sivalingam JJ, O'Neill BJ, Staas WE Jr. Transverse myelitis secondary to coexistent Lyme disease and babesiosis. J Spinal Cord Med 2003; 26(2): 168-171.
255. Shoemaker RC, Hudnell HK, House DE, Van Kempen A, Pakes GE,COL40155 Study Team. Atovaquone plus cholestyramine in patients coinfected with Babesia microti and Borrelia burgdorferi refractory to othertreatment. Adv Ther 2006; 23(1): 1-11.
256. Skotarczak B, Wodecka B, Cichocka A. Coexistence DNA of Borreliaburgdorferi sensu lato and Babesia microti in Ixodes ricinus ticks from north- western Poland. Ann Agric Environ Med 2002; 9(1): 25-28.
257. Skotarczak B, Rymaszewska A, Wodecka B, Sawczuk M. Molecular evidenceof co-infection of Borrelia burgdorferi sensu lato, human granulocyticehrlichiosis agent, and Babesia microti in ticks from northwestern Poland. J Parasitol 2003; 89(1): 194-196.
258. Halos L, Jamal T, Maillard R, et al. Evidence of Bartonella sp. in questing adult and nymphal Ixodes ricinus ticks from France and co-infection with Borrelia burgdorferi sensu lato and Babesia sp. Vet Res 2005; 36(1): 79-87.
259. Schwartz I, Fish D, Daniels TJ. Prevalence of the rickettsial agent of human granulocytic ehrlichiosis in ticks from a hyperendemic focus of Lyme disease. N Engl J Med 1997; 337(1): 49-50.
260. Hermanowska-Szpakowicz T, Skotarczak B, Kondrusik M, et al. Detecting DNAs of Anaplasma phagocytophilum and Babesia in the blood of patients suspected of Lyme disease. Ann Agric Environ Med 2004; 11(2): 351-354.
261. Arnez M, Luznik-Bufon T, Avsic-Zupanc T, et al. Causes of febrile illness after a tick bite in Slovenian children. Pediatr Infect Dis 2003; 22(12): 1078-1083.
262. Stricker RB, Gaito A, Harris NS, Burrascano JJ. Co-infection in patients withlyme disease:how big a risk? Clin Infect Dis 2003; 37(9): 1277-1278.
263. Krause PJ, Telford SR 3rd, Spielman A, et al. Concurrent Lyme disease and babesiosis. JAMA 1996; 275(21): 1657-1660.
264. Wang TJ, Liang MH, Shangha O, et al. Coexposure to Borrelia burgdorferi and Babesia microti does not worsen the long-term outcome of lyme disease. Clin Infect Dis 2000; 31(5): 1149-1154.
265. Krause PJ, McKay K, Thompson CA, et al. Disease-specific diagnosis of coinfecting tickborne zoonosis:babesiosis, human granulocytic ehrlichiosis,and Lyme disease. Clin Infect Dis 2002; 34(9): 1184-1191.
266. Hatcher JC, Greenberg PD, Antique J, Jimenez-Lucho VE. Severe babesiosisin Long Island:review of 34 cases and their complications. Clin Infect Dis 2001; 32(8): 1117-1125.
267. Krause PJ, Telford SR 3rd, Spielman A, et al. Concurrent Lyme disease and babesiosis.Evidence for increased severity and duration of illness. JAMA 1996; 275(21): 1657-1660.
268. Reubush TK 2nd, Cassaday PB, Marsh HJ, et al. Human babesiosis on Nantucket Island.Clinical features. Ann Intern Med 1977; 86(1): 6-9.
269. White DJ, Talarico J, Chang HG, Birkhead GS, Heimberger T, Morse DL. Human babesiosis in New York State:Review of 139 hospitalized cases and analysis of prognostic factors. Arch Intern Med 1998; 158(19): 2149-2154.
270. Krause PJ, Ryan R, Telford S 3rd, Persing D, Spielman A. Efficacy of immunoglogulin M serodiagnostic test for rapid diagnosis of acute babesiosis. J Clin Microbiol 1996; 34(8): 2014-2016.
271. Krause PJ, Telford SR 3rd, Ryan R, et al. Diagnosis of babesiosis: evaluationof a serologic test for the detection of Babesia microti antibody. J Infect Dis 1994; 169(4): 923-926.
272. Vannier E, Gewurz BE, Krause PJ, et al. Human babesiosis, Infect Dis Clin North Am 2008; 22: 469.
273. Shaked Y, Samra Y. Q fever meningoencephalitis associated with bilateral abducens nerve paralysis, bilateral optic neuritis and abnormal cerebrospinal fluid findings. Infection 1989; 17(6): 394-395.
274. Brooks RG, Licitra CM, Peacock MG. Encephalitis caused by Coxiella burnetii. Ann Neurol 1986; 20(1): 91-93.
275. Kofteridis DP, Mazokopakis EE, Tselentis Y, Gikas A. Neurological complications of acute Q fever infection. Eur J Epidemiol 2004; 19(11): 1051-1054.
276. Walid MS, Ajjan M, Ulm AJ. Subacute Transverse myelitis with Lyme profile dissociation. Ger Med Sci 2008; 6:Doc04.
277. Bernit E, Pouget J, Janbon F et al. Neurological involvement in acute Q fever:a report of 29 cases and review of the literature. Arch Intern Med 2002; 162(6): 693-700.
278. Bonetti B, Monaco S, Ferrari S, Tezzon F, Rizzuto N. Demyelinating polyradiculoneuritis following Coxiella burnetti infection (Q fever). Ital J Neurol Sci 1991; 12(4): 415-417.
279. Nikkari S, Roivainen A, Hannonen P, et al. Persistence of parvovi-rus B19 in synovial fluid and bone marrow. Ann Rheum Dis 1995; 54(7): 597-600.
280. Kühl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112(13): 1965-1970.
281. Tschöpe C, Bock CT, Kasner M, et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005; 111(7): 879-886.
282. Donoso Mantke O, Nitsche A, Meyer R, Klingel K, Niedrig M. Analysing myocardial tissue from explanted hearts of heart transplant recipients and multi-organ donors for the presence of parvovirus B19 DNA. J Clin Virol 2004; 31(1): 32-39.
283. Schenk T, Enders M, Pollak S, Hahn R, Huzly D. High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy. J Clin Microbiol 2009; 47(1): 106-110.
284. Lindblom A, Isa A, Norbeck O, et al. Slow clearance of human parvovirus B19 viremia following acute infection. Clin Infect Dis 2005; 41(8): 1201-1203.
285. Lowry SM, Brent LH, Menaldino S, Kerr JR. A case of persistent parvovirusB19 infection with bilateral cartilaginous and ligamentous damage to thewrists. Clin Infect Dis 2005; 41(4):e42-e44.
286. nd ed, Blaser MJ, Eds, Washington DC: ASM Press 2000; p. 121.
287. Whitehouse CA, Balbo PB, Pesci EC, Cottle DL, Mirabito PM, Pickett CL. Campylobacter jejuni cytolethal distending toxin causes a G2-phase cell cycle block. Infect Immun 1998; 66(5): 1934-1940.
288. Pickett CL, Pesci EC, Cottle DL, Russell G, Erdam AN, Zeytin H. Prevalence of cytolethal distending toxin production in Campylobacter jejuni and relatedness of Campylobacter sp. cdtB gene. Infect Immun 1996; 64(6): 2070-2078.
289. nd ed, Philadelphia: 2002; Lippincott Williams and Wilkens, p. 719.
290. Hannu T, Kauppi M, Tuomala M, Laaksonen I, Klemets P, Kuusi M. Reactive arthritis following an outbreak of Campylobacter jejuni infection. J Rheumatol 2004; 31(3): 528-530.
291. Garg AX, Pope JE, Thiessen-Philbrook H, Clark WF, Ouimet J. Walkerton Health Study Investigators. Arthritis risk after acute bacterial gastroenteritis. Rheumatology (Oxford) 2008; 47(2): 200-204.
292. Townes JM, Deodhar AA, Laines ES, et al. Reactive arthritis following culture-confirmed infections with bacterial enteric pathogens in Minnesota and Oregon:a population-based study. Ann Rheum Dis 2008; 67(12): 1689-1696.
293. Shenker BJ, Besack D, McKay T, Pankoski L, Zekavat A, Demuth DR. Induction of cell cycle arrest in lymphocytes by Actinobacillus actinomycetemcomitans cytolethal distending toxin requires three subunits for maximum activity. J Immunol 2005; 174(4): 2228-2234.
294. Sorvillo FJ, Lieb LE, Waterman SH. Incidence of campylobacteriosis among patients with AIDS in Los Angeles County. J Acquir Immune Defic Syndr 1991; 4(6): 598-602.
295. Melamed I, Bujanover Y, Igra YS, Schwartz D, Zakuth V, Spirer Z. Campylobacter enteritis in normal and immunodeficient children. Am J Dis Child 1983; 137(8): 752-753.
296. Taylor DE, Chang N. In vitro susceptibilities of Campylobacter jejuni and Campylobacter coli to azithromycin and erythromycin. Animicrob Agents Chemother 1991; 35(9): 1917-1918.
297. Gaunt PD, Piddock LJ. Ciprofloxacin resistant Campylobacter spp. in humans:an epidemiological and laboratory study. J Antimicrob Chemother 1996; 37(4): 747-757.
298. Lariviere LA, Gaudreau CL, Turgeon FF. Susceptibility of clinical isolates of Campylobacter jejuni to twenty-five antimicrobila agents. J Antimicrob Chemother 1986; 18(6): 681-685.
299. Ahvonen P, Sievers K, Aho K. Arthritis associated with Yersinia enterocolitica infection. Acta Rheumatol Scand 1969; 15(3): 232-253.
300. Panush RS, Wallace DJ, Dorff RE, Engleman EP. Retraction of the suggestion to use the term "Reiter's syndrome" sixty-five years later:the legacy of Reiter, a war criminal, should not be eponymic honor but rather condemnation. Arthritis Rheum 2007; 56(2): 693-694.
301. Keynan Y, Rimar D. Reactive arthritis - the appropriate name. Isr Med Assoc J 2008; 10(4): 256-258.
302. Hannu T, Inman R, Granfors K, Leirisalo-Repo M. Reactive arthritis or post-infectious arthritis? Best Pract Res Clin Rheumatol 2006; 20(3): 419-433.
303. th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999. J Rheumatol 2000; 27(9): 2185-2192.
304. Leirisalo-Repo M. Reactive arthritis. Scand J Rheumatol 2005; 34(4): 251-259.
305. Leirisalo-Repo M, Sieper J. Reactive arthritis: epidemiology, clinical features and treatment In: Weisman MH, van der Heijde D, Reveille JD, Eds. Ankylosing spondylitis and thespondyloar-thropathies. Philadelphia: Mosby Elevier 2006; pp. 53-64.
306. Yu DT, Pathogenesis of reactive arthritis. Intern Med 1999; 38(2): 97-101.
307. Kvien TK, Gaston JS, Bardin T, et al. Three month treatment of reactive arthritis with azithromycin:a EULAR double blind, placebo controlled study. Ann Rheum Dis 2004; 63(9): 1113-1119.
308. Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, et al. Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis. Ann Rheum Dis 2003; 62(9): 880-884.
309. Lauhio A, Leirisalo-Repo M, Lähdevirta J, Saikku P, Repo H. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 1991; 34(1): 6-14.
310. Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, et al. Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis 2000; 59(7): 565-570.
311. Laasila N, Laasonen L, Leirisalo-Repo M. Antibiotic treatment and long term prognosis of reactive arthritis. Ann Rheum Dis 2003; 62(7): 655-658.
312. Putschky N, Pott HG, Kuipers JG, Zeidler H, Hammer M, Wollenhaupt J. Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis:a prospective, double-blind trial. Ann Rheum Dis 2006; 65(11): 1521-1524